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The combination of Darunavir (DRV) and Ritonavir (RTV) at a dose of 800/100mg has exhibit durable efficacy in both 
untreated and treated HIV positive patients with no observed DRV resistance-associated mutations (RAMs) and the RTV 
improves the pharmacokinetic profile of DRV by enhancing its bioavailability. Hence a sensitive high-performance liquid 
chromatography-tandem mass spectrometry (HPLC-MS/MS) method has been developed and validated for the simultaneous 
quantification of Darunavir (DRV) and Ritonavir (RTV) in human plasma. The chromatographic separation has been 
accomplished on Thermo Hypersil Gold (50×4.6mm, 3μ) analytical column using isocratic elution using 0.1% Formic Acid 
buffer solution/Acetonitrile (50:50, v/v) at a flow rate of 0.6 mL/min. The linearity of the method ranged 150.000 ng/mL to 
15000.000 ng/mL & 10.000 ng/mL to 3000.00 ng/mL for DRV & RTV respectively, using 100 μL of plasma. The method 
was completely validated for its sensitivity, selectivity, linearity, accuracy and precision, recovery, matrix effect, stability, 
and dilution integrity. The absolute recovery for DRV ranged from 79.12 to 72.71 % while for RTV it ranged from 
63.39% to 66.99 %. For DRV-D9 and RTV-D6 the recovery rates are 94.19 and 80.05% respectively. The method exhibit 
good intra-day and inter-day precision with low % CV of less than 5.0% at each quality control level for both the analytes. 
The developed method has been applied successfully for pharmacokinetic study in healthy humans by oral administration of 
Darunavir/Ritonavir tablets 400/50 mg (dose; 02x400/50 mg) in 77 healthy male volunteers under fed condition. 
Keywords: Bioanalytical, Bioequivalence, Darunavir (DRV), Good Clinical Practice, LCMS/MS method Validation, 
Lower Limit of Quantification, Pharmacokinetic, Ritonavir (RTV) 
There has been a remarkable transformation, in the 
treatment of HIV in recent years due to evolving 
potent antiretroviral (ART) combination therapies 
with better tolerability leading   to increased life 
expectancy of HIV patients
1-3
. The most common 
antiviral dosing regimen recommended was a vital 
combination of two nucleotide reverse transcriptase 
inhibitors (NRTIs) with a third antiretroviral drug, 
preferably a protease inhibitor (PI) boosted with RTV. 
The HIV protease inhibitor DRV, boosted by RTV 
(DRV/RTV) is prescribed as a once-daily (q24h) ART 
at standard dosage regimens of 800/100 mg once 
daily in naive patients and 600/100 mg twice daily in 
treatment-experienced patients and with no DRV 
resistance-associated mutations (RAMs). 
DRV a substrate and mild inhibitor of CYP3A4 is 
extensively metabolized by CYP3A4 in the liver and 
intestinal lumen
4
. RTV a strong CYP3A4 inhibitor 
prevents this fast pass metabolism of DRV and 
increases its bioavailability
5
. RTV further acts as a 
pharmacokinetic enhancer by strongly inhibiting the 
DRV transporter P-glycoprotein (P-gp) that result in 
2.7-fold increase in intestinal permeability of DRV in 
mice and Caco-2 monolayers models. In a study of 
HIV-negative in healthy volunteers the absolute 
bioavailability of DRV (600 mg once daily) was 
observed to increase 82% in presence of RTV (100mg 
twice daily) in comparison to DRV was administered 
alone for which the observed increase was 37%.
6,7 
However increasing the RTV dose at 200 mg twice 
daily with DRV 600mg once daily did not result in 
any relevant increase in plasma concentrations for 
DRV indicating 100 mg twice daily dose of RTV to 





DRV in combination with RTV was evaluated 
in four different doses (600 or 400 mg twice daily, 
and 800 or 400 mg once daily with 100 mg RTV) for 
efficacy and safety in a treatment-experienced 
HIV-infected population of patients (pivotal POWER 
1 and 2 clinical trials) in which the highest virological 




response was obtained with twice daily 600/100 mg 
of DRV/RTV combination and was approved for 
treatment-experienced patients
8
. In another subgroup 
analysis for initial ART therapy similar responses was 
observed for the 800 mg once-daily and the 600 mg 
twice-daily doses leading to approval of the single 
daily 800 mg dose for naive patients
9
. 
The study of pharmacokinetic parameters is an 
important aspect for the reduction of Antiretroviral 
dose reduction that simplify the ART dosing regimens 
with reduced pill burden and less side-effects in HIV 
patients. Bioanalytical methods for measuring plasma 
drug concentration are indispensable to understand 




bioanalytical assays have been developed for the 
DRV and RTV in combination with other anti-
retroviral or separately for each one of them
11
, here 
we developed and validated a bioanalytical method 
for the simultaneous quantification of both DRV and 
RTV and an extensive validation studies had been 
performed to ensure the selectivity and sensitivity of 
the developed method. The developed model is 
simple, sensitive, selective, efficient, and validated 
and is reliable for the determination of DRV & RTV 
to ensure that the method is selective, specific, precise 
& accurate for the determination of DRV & RTV to 
support the bioequivalence and bioavailability study 
of DRV & RTV. The chemical structure of Darunavir 
(A) and Ritonavir (B) is given in Fig. 1. 
 
Experimental Section  
The reference standard samples of DRV (98.6%) 
and RTV (99.5%) were obtained from Mylan 
laboratories Ltd. and DRV-D9 (99.25%) and RTV-D6 
(96.20%) were obtained from TLC pharmachem and 
TLC pharmaceuticalrespectively. Water used for the 
LC-MS/MS analysis was prepared by using Milli Q 
water purification system procured from Millipore 
(Bangalore, India). Formicacid of suprapure gradewas 
purchased from Merck. HPLC grade of acetonitrile 
and methanol were purchased from J.T. Baker 
(Phillipsburg, USA). The control human plasma 
sample was procured from Deccan’s Pathological 
Lab’s (Hyderabad, India). 
 
LC–MS system and conditions  
An HPLC system (Shimadzu, Kyoto, Japan) 
consisting of a Thermo Hypersil Gold column 
(50×4.6mm, 3μ), a LC-20 AD Vp Pump (Shimadzu), 
an auto sampler (Shimadzu-SIL-HTc) and a solvent 
degasser (DGU-20A3) were used for the study. The 
processed samples after reconstitution were injected 
(5µL)into the column maintained at a temperature of 
40 ± 5 ºC. An isocratic mobile phase composition of 
acetonitrile and 0.1% formic acid (50:50) was  
used for the separation of the analytes transferred at 
0.600 mL/min flow rate (with splitter of 50:50) into 
ionization chamber (electrospray mode) of the mass 
spectrometer. The detection and quantification of the 
analytes and the internal standards in MS-MS positive 
ionization mode was selected using MDS Sciex API-
4000 mass spectrometer (Foster City, CA, USA) 
equipped with a Turboionspray™ interface at 450 ºC. 
The different source parameters such as the nebulizer 
gas (GS1-45 psi), curtain gas (CUR-20 psi), auxiliary 
gas (GS2-55 psi) and collision gas (CAD-7 psi), ion 
spray voltage (5500V) were optimized to obtain better 
detection response for the analytes and the internal 
standard within 5.5 min run time. The compound 
parameters were also optimized such as the 
declustering potential (DP), collision energy (CE), 
entrance potential (EP) and collision cell exit potential 
(CXP) were 70, 20, 10, 10 V for DRV and DRV d9 
and 78, 30, 10, 10 V for RTV and RTV D6 
respectively. Multiple-reaction monitoring mode 
(MRM) was selected for detection of the ions, by 
selecting the transition pairs of m/z 548.300 precursor 
ion to the m/z 392.300 for DRV, m/z 557.400 
precursor ion to the m/z 401.200 for DRV D9 for the 
IS, andm/z 721.400 precursor ion to the m/z 296.100 
for RTV, m/z 727.400 precursor ion to the m/z 
302.100 for RTV d6 for the IS respectively. The 
quadrupoles Q1 and Q3 were set on unit resolution 
and the data analysis was performed using Analyst 
software™ (version 1.5.1).  
 
Stock solutions 
Stock solutions of DRV, RTV were prepared 
separately by dissolving in methanol at 2 mg/mL and 
1mg/mL concentration respectively. RTV D6 and 
DRV D9 stock solutions were prepared by dissolving 
in methanol at 0.2 mg/mL and 0.4 mg/ml 
 
 
Fig. 1 — Chemical structure of (A) Darunavir (DRV) and (B) 
Ritonavir (RTV). 




concentration respectively. Different concentrations 
of the working solutions were prepared by  
stock dilution using diluent [methanol and water 
(60:40%, v/v)]. Intermediate solution containing both 
200.000 µg/mL DRV and 100.000 µg/mL RTV were  
prepared by transferring both 1000µL of DRV stock  
solution (2000.000µg/mL) and RTV stock solution 
(1000.000µg/mL) using diluent in 10 mL volumetric 
flask. RTV-D6 and DRV-D9 working internal standard 
solution by transferring 1250 µL of RTV-D6 and 3750 
µL of DRV-D9 stock solutions with diluent into a  
50 mL of a volumetric flask. 
 
Sample pretreatment 
A 100 µL aliquot of human plasma sample was 
mixed with 25 µL of working internal standard (RTV-
D6+DRV-D9 -5.000 µg/mL and 30.000 µg/mL). To 
this, 200µLof ExtractionAdditive (Milli-Q/HPLC 
grade Water) was added and vortexed for 10-20 
seconds and keep aside for Solid phase extraction.  
The conditioning and equilibration of cartridge 
(Oasis HLB, 30 mg, 1cc) were performed with 1mL 
of Methanol followed by 1mL of Milli-Q water.  
The spiked plasma samples of volume 325 µL (100 
µL aliquot of human plasma + 25 µL of Working 
internal standard + 200µL of Extraction Additive) 
were loaded into cartridge and washed with 1mL of 
Milli-Q/HPLC grade water followed by washing with 
1ml of 5% Methanol in water. Elution was performed 
by using methanol and evaporated the sample to 
complete dryness under a stream of nitrogen gas at 
≤50C. Reconstituted the residue with 1.000 mL of 
reconstitution solution (0.1% Formic Acid buffer 
solution with 250mL of Acetonitrile/Mobile phase). 
From these, a 5.0µL aliquot was injected into the 
chromatographic system. The developed method  
was completely validated by performing selectivity, 
sensitivity, linearity, precision and accuracy, 
recovery, matrix effect, stability, and dilution integrity 
experiments. 
 
Calibration curves and Limit of quantitation 
The assay was validated with a standard curve 
range of 150.074 to 15007.413 ng/mL & 10.007 to 
3002.015 ng/mL for DRV &RTV respectively. The 
standard curve consisted of nine non-zero calibration 
standards, along with matrix blanks (with and without 
the addition of internal standard). The lowest 
standardconcentration (150.074 ng/mL & 10.007 
ng/mL for DRV & RTV respectively) defined the 
lower limit of quantitation (LLOQ) for the assay, 
while the standard with the highest concentration 
(15007.413 ng/mL & 3002.015ng/mL for DRV & 
RTV respectively) defined the upper limit of the assay 
(ULOQ). 
Linearity is defined as the square of the correlation 
coefficient (r) obtained from weighted linear 
regression of peak area ratio (analyte/internal 
standard) versus concentration. The criterion for 
acceptable linearity was ≥ 0.99. All validation 
standard curves used for accuracy and precision 
determinations surpassed this limit with r values of 
greater than 0.99. In any batch not less than 75% of 
all standards samples and 67% of all QCs (50% at 
each level) samples were required to have a 
percentage deviation within ± 15% except LLOQ 
where a percentage deviation within ± 20%. 
 
Selectivity, matrix effect, recovery and carry over 
The blank plasma samples 14 different lots (8 normal, 
2 (0.5%) Haemolysed, 2 (1.0%) Haemolysed &  
2 lipemic were evaluated for selectivity experiment 
during the validation experiment. The specificity run 
was performed using six extracted LLOQ standards. 
The analyte response in the blank plasma was 
compared to the LLOQ standard mean area of DRV, 
RTV and internal standards from the 14 different 
plasma lots.  
To evaluate the matrix factor Six lots (4 Normal, 1 
(1%) Haemolysed & 1 Lipemic) of interference free 
blank matrix from individual donor were taken, 
processed in triplicate from each lot and extracted 
according to the analytical method procedure. The 
post extracted LQC & HQC samples were obtained 
by spiking the analyte and internal standard into the 
extracted plasma blank samples. In the next step  
12 aqueous (without matrix) LQC & HQC samples 
were prepared and compared with the post extracted 
LQC & HQC samples and calculation of the matrix 
factor was done for each matrix lot by calculating the 
ratio the mean peak area of unextracted samples to the 
peak area of post extracted samples. Additionally, 
Internal Standard Normalized Matrix Factor was also 
evaluated by calculating matrix factor of analytes  
by matrix factor of Internal Standards at each lot  
of matrix. 
The extracted analyte peak area was compared with 
the non-extracted standard peak area to calculate 
recoveries of DRV and RTV. The recovery of DRV 
and RTV was calculated at a 450.0, 30.0 (LQC), 
7500.0, 1500.0 (MQC-1) and 11300.0, 2300.0 (HQC) 
ng/mL, concentration levels respectively, and the IS 
was determined at concentration of (RTV-D6+DRV-




D9 -5.000 µg/mL and 30.000 µg/mL). In order to 
extend the upper concentration limit dilution integrity 
was performed with acceptable precision and 
accuracy. The dilution integrity experiment was 
performed by using 4 x ULOQ samples and dilution 
of the samples by using blank plasma was performed 
at six replicates of five times and ten times dilution  
(1 in 10 dilution) and freshly spiked calibration curve 
concentrations were determined against nominal 
comparison concentrations.  
 
Accuracy and Precision  
The intra batch accuracy and precision for DRV 
and RTV was determined by 4 sets of calibration 
curves and 4 sets of QC samples. The quality control 
samples (LLOQQC, LQC, MQC1, MQC2 and HQC) 
were taken in 6 replicates. The inter batch accuracy 
and precision was analyzed by performing four 
accuracy and precision batches using 1 sets of 
calibration curves and 6 replicates of QC samples 
(LLOQQC, LQC, MQC1, MQC2 and HQC). The 
batch acceptance criteria for the calibration curve 
standard and quality control samples were met if the 
accuracy of the samplesiswithin ±15% deviation (SD) 
from the nominal values, except for LLOQ QC,  
it is ±20%. The precision of 15% relative standard 
deviation (RSD), is accepted for   the calibration 
curve standard and quality control samples except  
for LLOQ, where it should be 20%. The batch 
acceptance criteria were met if 67% of the total 
quality control samples and 50% at each quality 




The ruggedness experiment was evaluated by 
processing one P&A by different analyst and 
reinjecting one P&A batch samples on different 
column with same specification. The run consisted of 
a calibration curve standard and 6 replicates at each of 
LLOQQC, low (LQC), medium (MQC1), medium 
(MQC2) and high (HQC) concentrations. The 
ruggedness experiment was also evaluated by 
reinjecting samples of one P&A on different  
column with same make and specification. 




The dilution integrity experiment was performed 
using five times dilution (1 in 5 dilutions) and ten-
time dilution (1 in 10 dilutions) of six replicates of 
approx. 4x ULOQ samples and the concentrations 
were calculated using the nominal concentrations of 
freshly spiked calibration curve samples. 
 
Stability and re-Injection reproducibility 
The bulk spiked samples were used for matrix 
stability experiments and the accuracy of these 
samples was determined previously to satisfy the 
acceptance criteria after spiking with the analyte. The 
bulk spiked samples of six replicates of LQC and 
HQC samples were determined for different stability 
conditions like the study sample analysis conditions. 
These stability experiments for the samples were 
performed in a single run where the samples were 
processed and analyzed with freshly processed 
calibration standards (CS) and six sets of QC samples.  
The quality control samples of one P&A batch after 
analysis was reinjected to check the reproducibility 
bykeeping the samples in the auto sampler at 5°C and 
reinjected after more than 40 hrs. to check the 
acceptance limits of accuracy (±15% of their 
respective nominal concentration) and precision 
(%CV ≤15). 
 
Pharmacokinetic study design 
A randomized, open-label, balanced, two-
treatment, two-period, two-sequence, single dose, 
crossover oral bioequivalence study was planned  
as per the ICH GCP guidelines. Bioequivalence  
study was conducted on 77 male subjects under 
Fedconditions.The study was conducted in groups due 
to relatively large number of subjects in the study. 
RTV half-life is 3-5 hours and the terminal 
elimination half-life of DRV was approximately  
15 hours when co-administered with RTV. A washout 
period of 16 days was considered to be adequate.  
In this study, the pharmacokinetic profile of the test 
product (A) was characterized relative to that of the 
reference product (B) to assess bioequivalence for 
DRV/RTV tablets 400/50mg (Dose; 02 x 400/50 mg). 
Being a bioequivalence study with a crossover design, 
each subject act as his own control. Therefore, no 
control group was required for the study. The protocol 
was approved by the ethics committee and informed 
written consent was provided by the volunteers. After 
oral administration Blood samples were collected at 
pre-dose and 0.33, 0.67, 1, 1.33, 1.67, 2, 2.33, 2.67, 3, 
3.33, 3.67, 4, 4.5, 5, 5.5, 6, 7, 8, 10, 12, 16, 24, 36, 48 
and 72 hrs, in K3-EDTA vacutainer collection tubes 
(BD, Franklin, NJ, USA). The collected plasma 
samples were stored at –70 ± 15C until use. Plasma 
samples were spiked with the IS and processed as per 




the extraction procedure described earlier. The subject 
sample analysis was performed along with standard 
samples (calibration curve standards) and different 
level of QC samples (LQC, M1QC, M2QC and HQC) 





During method development for the simultaneous 
quantification of DRV and RTV different detection 
and chromatography parameters were evaluated to 
optimize the detection of analytes. In positive 
ionization mode the mass parameters showed good 
response. The analyte response was optimized using 
the multiple reaction monitoring (MRM) modes. The 
monitoring of the most sensitive mass transition was 
performed by using the protonated parent ion in the 
Q1 spectrum form of each analyte and IS, [M+H]
+
ion 
served as the precursor ion for Q3 product ion spectra. 
The mass spectrometry specification for DRV  
and RTV and the respective internal standards  
are mentioned in Table 1. The multiple-
reactionmonitoring mode (MRM) was performed by 
monitoring the transition pairs of m/z 548.300 
precursor ion to the m/z 392.300 for DRV, m/z 
557.300 precursor ion to the m/z 401.200 for DRV-d9 
for the IS, and m/z 721.400 precursor ion to the m/z 
296.100 for RTV, m/z 727.400 precursor ion to the 
m/z 302.100 for RTV-d6 for the IS respectively.  
 
Chromatography optimization 
In order to achieve increased intensity and good 
resolution with shorter run time several trials were 
conducted to optimize the chromatographic conditions 
such as the composition of the mobile phase. Better 
response for both the analytes and the IS was 
observed using 0.1% Formic acid: Acetonitrile 
(50:50) while setting the MS detection in the positive 
ionization mode. The mobile phase delivered at a flow 
rate of 0.600 mL /min using the Thermo Hypersil 
Gold column (50×4.6mm, 3μ) provided better results 
such as good peak shape and response for both the 
analytes and IS. The retention time of DRV and RTV 
were 2.32 and 3.91 mins respectively and for the 
internal standard (DRV-D9 and RTV-D6) it was  
2.30 and 3.86 mins respectively allowing a run time 
of 5.50 min. 
 
Sample Pre-treatment Optimization  
The low matrix effect and better recovery was 
obtained by using the solid phase extraction (SPE) 
technique that provided better extraction of the drug 
and IS from the matrix compared to the LLE 
technique. The auto sampler wash solution was 
optimized to avoid any carry over effect to 50% 
Acetonitrile/water. The intended sensitivity was 
obtained by adjusting the plasma sample volume to 
100μL. The chromatographic conditions, extraction 
procedure and detection parameters were optimized to 
obtain accurate and precise detection for the analytes 
in human plasma. 
 
Calibration curves and limit of quantitation 
The assay was validated with a standard curve 
range of 150.074 to 15007.413 ng/mL & 10.007 to 
3002.015 ng/mL for DRV &RTV respectively. The 
weighing factor selected was 1/x
2
. The measured 
volume of the working solutions (20 µL of DRV and 
20 µL of RTV) for calibration curve (CC) standard 
samples were spiked in 960 µL of control human 
plasma with an, giving final concentrations of 150.0, 
300.0, 800.0, 1200.0, 3000.0, 6000.0, 9000.0, 
12000.0, and 15000.0 ng/mL for DRV, and 10.0, 
20.0, 60.0, 200.0, 600.0, 1200.0, 1800.0, 2400.0, and 
3000.0 ng/mL for RTV. In each batch the CC samples 
were analyzed along with the quality control (QC) 
samples. The QC samples were prepared at five 
different concentration levels of 150.0 (LLOQ), 450.0 
(LQC), 3500.0 (M1QC), 7500.0 (M2QC) and 11300.0 
(HQC) ng/mL for DRV and 10.0 (LLOQ), 30.0 
(LQC), 300.0 (MQC1), 1500.0 (MQC2) and 2300.0 
(HQC) ng/mL for RTV in blank plasma. The prepared 
samples were stored at −70 ±15°C. The criterion  
for acceptable linearity was r ≥ 0.99. All validation 
standard curves used for accuracy and precision 
Table 1 — Mass spectrometry specification for DRV and RTV and therespective internal standards. 
Drug name DRV DRV-D9 RTV RTV-D6 
DP 70.00 70.00 78.00 78.00 
EP 10.00 10.00 10.00 10.00 
CE 20.00 20.00 30.00 30.00 
CXP 10.00 10.00 10.00 10.00 
Parent Mass 548.300 557.400 721.400 727.400 
Product Mass 392.300 401.200 296.100 302.100 
Dwell time (m sec) 200.00 200.00 200.00 200.00 
 




determinations surpassed this limit with r values of 
greater than 0.99. 
 
Selectivity, matrix effect, recovery and carry over 
In all plasma lots no significant interferences were 
observed (normal, lipemic, hemolysed) in the 
selectivity experiments for DRV, RTV and their 
respective Internal Standard. Matrix effect is 
investigated to ensure that precision, selectivity and 
sensitivity are not compromised by the matrix. For 
matrix effect no significant interference was observed 
at the RT of both the analytes as the % CV of IS 
normalized matrix factor for DRV and RTV was 
below 4% for both HQC and LQC level that was 
within acceptance criteria(<15%). 
The Meanrecovery values were approximately 
≥75% for DRV and ≥65% for RTV respectively. The 
difference in %CV of recoveries across each QC level 
was within 15% for both the analytes and also for the 
respective IS. The results are presented in Table 2. 
There was no observed significant autosampler 
injector carry over for the analyte and IS. 
 
Accuracy and precision  
The acceptance criteria for the QC samples except 
LLOQ QC were satisfied if the mean % nominal 
value and %CV were in range of 85-115% and less 
than 15%, respectively for all analytes. The precision 
and accuracy results in plasma quality control samples 
for intra-day and inter-day are summarized in Table 3. 
The LQC, MQC1, MQC2 and HQC samples had 
precision deviation values all within 15% of the 
relative standard deviation (RSD) at the intra-day and 
inter day experiments and for LLOQ the relative 
standard deviation (RSD) is within 20%. Similarly, 
the accuracy deviation values for the LQC, MQC1, 
MQC2 and HQC samples for the intra-day and inter-
day were all within 100 ± 15% of the actual values 
and for the LLOQ QCs level it is within 100± 20%. 
The obtained results satisfied the acceptance criteria 
in the precision and accuracy experiments. Thus, it 
indicates that method was accurate and precise over 




The mean % nominal value and %CV were in 
range of 85-115% and less than 15%, respectively 
across all QC levels for all analytes for ruggedness 
experiment involving different analyst, column and 
instrument. The run consisted of a calibration curve 
Table 2 — Matrix effect (factor)and recovery for DRV, RTV, DRV d9 and RTV-d6. 
Analyte Level Mean/ %CV of IS-normalized matrix factor Recovery(%)/CV(%) Mean recovery 
DRV HQC 0.984/3.24 74.80/5.58 76.11 
M2QC - 72.71/3.99 
M1QC - 79.12/4.81 
LQC 0.994/1.13 77.81/4.90 
RTV HQC 0.98/2.33 65.82/5.72 65.15 
M2QC - 63.39/4.74 
M1QC - 66.99/8.83 
LQC 0.999/1.88 64.41/9.98 
DRV d9 - 3.53/0.989 94.19/4.83 - 
RTV-d6 - 0.990/2.00 80.05/7.42 - 
 
Table 3 — Precision and accuracy results for DRV and RTV Precision and accuracy of DRV. 
 
Nominal concentration in 
ng/mL 
Intra-day (n=6) Inter-day (n=24) 
Mean CV (%) Accuracy (%) Mean CV (%) Accuracy (%) 
HQC (11321.688) 10709.917 3.53 94.60 10576.667 4.90 93.42 
MQC1(7501.118) 7764.232 4.85 103.51 7733.750 4.42 103.10 
MQC2(3500.522) 3687.759 2.34 105.35 3649.371 4.74 104.25 
LQC (452.067) 441.445 2.79 97.65 452.190 4.95 100.03 
LLOQQC (150.022) 152.072 4.96 101.37 153.156 4.33 102.09 
Precision and accuracy of RTV 
HQC (2302.918) 2330.272 1.23 101.19 2324.232 2.38 100.93 
MQC1(1501.903) 1488.061 2.35 99.08 1511.947 3.25 100.67 
MQC2(300.381) 307.362 1.95 102.32 307.849 3.91 102.49 
LQC (30.038) 28.705 2.62 95.56 29.868 4.71 99.43 
LLOQQC (10.013) 9.613 1.33 96.01 10.263 5.72 102.50 
 




standard and 6 replicates at each of LLOQQC, low 
(LQC), medium (MQC1), medium (MQC2) and high 
(HQC) concentrations. The precision (%CV) and 
accuracy (%Nom) of DRV & RTV QC samples was 
within the range viz.  the %CV is less than 15% and 
the mean % Nominal is between 85-115%. These 
results indicated that the method is rugged and 
reproducible even if sample processedby different 
analyst. The ruggedness experiment was also 
determined by calculating the precision and accuracy 
on different column with same make and specification 
by reinjecting the samples of one P&A batch and the 
results were found to be reproducible for both DRV & 
RTV. Ruggedness experiment was evaluated on 
different instrument of the same make with two P&A 
batches & Injector Carry Over. The correlation 
coefficient was found to be greater than or equal to 
0.9994 & 0.9992 for DRV & RTV respectively.The 
results are presented in Table 4 
 
Dilution integrity 
The dilution integrity experiment was performed 
using five (1 in 5 dilution) and ten times diluted  
(1 in 10 dilution) samples at six replicates of approx. 
4 x ULOQ samples and the concentrations were 
calculated and compared using calibration curve 
samples that are spiked freshly. The results were 
within the acceptance criteria. The results are 
presented in Table 5. 
 
Reinjection reproducibility and stability  
The QC samples of one P&A batch was used in 
partial reinjection reproducibility experiment by 
keeping them for approx. 44hr 21min in the auto 
sampler at 10°C and reinjected for analysis. The 
results confirmed that after reinjection in auto sampler 
at 5°C no significant variation was observed in the 
analyte concentration.  
Similar to partial reinjection reproducibility 
samples of one P&A batch was reinjected to 
determine the whole batch reinjection reproducibility 
experiment. The results are reproducible after 
reinjection for both DRV & RTV that proved the 
stability of the samples for approx. 42hr 57 min post 
extraction in autosampler. 
The stock (Prepared in Methanol) and working 
solutions of Darunavir, Ritonavir, Darunavir-D9  
and Ritonavir-D6 (Prepared in Methanol: Water 
Table 4 — Ruggedness experiment for DRV and RTV. 
 LLOQ QC LQC M1QC M2QC HQC 

































































































































{60:40})was found to be stable for 16 days in the 
refrigerator at 0-10ºC. The bench top stability was 
evaluated by retrieving 6 LQC and HQC samples 
from deep freezer condition and kept for 26 hr 58 min 
at room temperature after which they were processed 
and compared with freshly prepared comparison LQC 
and HQC samples and calibration standards samples. 
The mean % changes in concentrations were 
calculated to determine the stability period that was 
26 hrs 58 min at room temperature for both DRV & 
RTV.The results are presented in Table 6.  
The stability of the analytes in the biological matrix 
kept in dry ice during transportation was evaluated by 
keeping six HQC and LQC samples in dry ice for 
approximately 93 hr 56 min. 
The stability samples (HQC and LQC) after the 
desired period were processed and analysed along with 
freshly processed comparison samples (LQC and HQC 
samples) and calibration curve standards samples. The 
results prove the stability of both DRV &RTV during 
sample shipment in dry ice to be stable for approx. 93 
hr. 56 min.The results are presented in Table 6.  
The post extracted refrigerator stability in matrix 
was evaluated by processing six LQC and HQC 
samples in biological matrix kept for desired time 
duration. The six LQC and HQC samples after 
retrieval from deep freezer conditions were processed, 
reconstituted and stored for approx. 25 hr 42 min in 
refrigerator at 0-10ºC. The stability of the samples 
was compared with freshly prepared calibration 
standards and comparison samples (freshly processed 
LQC and HQC) after the desired period of time. The 
results indicate that post extracted samples kept at 
refrigerator conditions (0-10ºC) both DRV & RTV 
were stable for approx. 25 hr 42 min. The results are 
presented in Table 6.  
The freeze and thaw stability of the samples was 
evaluated at set temperatureof -70ºC &-20ºC by 
taking six replicates of LQC and HQC levels that 
were subjected to six freeze and thaw cycles (stability 
samples). After six freeze and thaw cycles these 
samples were processed and compared with freshly 
processed LQC and HQC samples (comparison 
samples) and calibration standard samples. The mean 
% change in concentrations were calculated to 
determine the stability of DRV& RTV that showed 
both the analytes are stable after six freeze thaw 
cycles.The results are presented in Table 6.  
The autosampler stability for DRV and RTV  
was assessed by taking 3 sets of LQC and HQC  
Table 5 — Dilution integrity results for DRV and RTV. 
Analyte QC level Dilution Factor: 5 Dilution Factor: 10 
 Mean CV % Bias Mean CV % Bias 
























*For DRV the DQC concentration is 60094.728 ng/mL. For RTV the DQC concentration is 12019.998 ng/mL. 
 
Table 6 — Stability study results for DRV and RTV. 
Storage period and storage condition QC level DRV RTV 
  Mean CV (%) Accuracy (%) Mean CV (%) Accuracy (%) 
Whole Blood Stability (RT) 
(02 Hr 09 min) 
HQC 1.4103 2.50 101.42 1.6591 1.36 102.53 
LQC 0.0618 3.56 100.82 0.0227 3.99 99.56 
Bench top stability 
(26 hrs 58 min) 
HQC 10211.957 3.16 90.20 2173.432 1.34 94.38 
LQC 430.835 4.46 95.30 28.298 3.24 94.21 
Auto sampler stability at 5±3°C  
(73 Hrs 15 min) 
HQC 10704.221 2.45 94.55 2279.130 2.99 98.97 
LQC 473.420 1.97 104.72 28.974 3.96 96.46 
freeze thaw cycles 
(-20±50C) for 6 cycles 
HQC 10484.914 3.43 92.61 2217.322 2.18 96.28 
LQC 440.797 4.87 97.51 27.247 3.19 90.71 
freeze thaw cycles 
(-70±150C) for 6 cycles 
HQC 10565.812 2.70 93.32 2197.791 3.29 95.44 
LQC 459.399 3.13 101.62 27.118 2.77 90.28 
Dry Extract Stability (RT) 
26 hrs 12 min 
HQC 10014.516 2.58 88.45 2120.150 4.42 92.06 
LQC 418.835 3.10 92.65 27.896 2.96 92.87 
Post Extracted Stability (RF) 
25 hrs 42 min 
HQC 10073.584 3.22 88.98 2232.473 1.66 96.94 
LQC 431.825 3.01 95.52 28.068 1.84 93.44 
Coolant Stability 
93 Hrs 56 min          
HQC 9765.589 3.80 86.26 2109.550 2.82 91.60 
LQC 414.419 4.34 91.67 27.221 2.74 90.62 
 




(6 samples at each level). The initial samples were 
analysed at 0.00 hr. followed by second batch of 
processed samples that were kept at 5ºC and analysed 
after 73 Hrs 15 min. The comparison of the second 
batch samples were done against the initial set 
samples along with freshly prepared calibration 
standard samples. The mean % change in 
concentrations during stability period were calculated 
to determine the stability of DRV and RTV. The 
results indicated both DRV and RTV were stable at 
5°C for approx. 73 Hrs. 15 min.The results are 
presented in Table 6.  
The whole blood stability was performed by 
spiking six replicates of LQC and HQC samples of 
whole blood (Stability samples) and kept at room 
temperature. The comparison samples consisted of six 
aliquots of whole blood at HQC and LQC levels, 
which were aliquoted separately and compared with 
the stability samples after a period of 02 hr 09 min. 
The separation of the plasmawas done by centrifuging 
both the stability & comparison samples with a speed 
of 3000 RPM at 4°C for about 10 min. The processing 
of the plasma samples was done as per the specified 
method. The results are presented in Table 6.  
The dry extract stability of DRV & RTV was 
performed by storing the dry extract (after extraction 
and sample preparation and no reconstitution 
solution) in the refrigerator (0-10ºC) and compared 
with the freshly prepared extracted replicates of LQC 
and HQC concentrations. The LQC and HQC 
concentrations for DRV & RTV in six replicates after 
extraction and in dry extract conditions were kept for 
approx. 26 hr 12 min in a refrigerator at 0-10ºC prior 
to sample analysis. The dry extract samples were 
compared with freshly prepared comparison (LQC & 
HQC) samples and calibration curve standards. The 
results are presented in Table 6. The results indicate 
both DRV & RTV were stable in dry extract for at 




The mean and SD of pharmacokinetic parameters 
estimated for test product (A) and reference product 
(B) were listed in Table 7. The geometric least 
squares mean, ratio of test product (A) and reference 
product (B),(A /B), 90% confidence intervals, Intra 
Subject Variability (CV in%) and power (in %) for 
the untransformed pharmacokinetic parameters Cmax, 
AUC0-t and AUC0-inf for Darunavir and Ritonavir 
were summarizedin Table 8 
The ratio of geometric least squares mean for the 
Cmax of test product (A) and reference product (B) 
treatments of log-transformed pharmacokinetic 
parameter Cmax was 114.19%. The two one-sided 90% 
confidence interval for the ratio of the geometric least 
squares mean was found 110.39-118.13 % with power 
Table 7 — Pharmacokinetic parameters for DRV in test and reference product under fed conditions. 
Parameters (Units) Un-transformed Data (Mean ± SD) 
Test Product(A) n=77 Reference Product (B) n=77 
*Tmax (hr) 4.00(1.33-5.00) 4.00(1.33-5.00) 
Cmax (ng/mL) 9152.511±2074.3019 7999.547±1733.2324 
AUC0-t (ng.hr/mL) 96420.313±31248.6686 82021.719±27910.2291 
AUC0-inf (ng.hr/mL) 102385.648±33664.6866 87324.115±28510.3070 
Kel (1/hr) 0.101±0.0276 0.100±0.0289 
t½ (hr) 7.368±1.9736 7.471±2.1343 
(AUC0-t/AUC0-inf)*100 5.572±5.6187 6.278±5.7754 
*Median, Minimum and Maximum values reported for Tmax. 
 
Table 8 — Pharmacokinetic parameters for RTV in test and reference product under fed conditions. 
Parameters (Units) Un-transformed Data (Mean ± SD) 
Test Product(A) n=77 Reference Product (B) n=77 
*Tmax (hr) 4.50(2.33-6.00) 4.50(3.00-6.00) 
Cmax (ng/mL) 933.797±341.1617 830.664±308.1748 
AUC0-t (ng.hr/mL) 6279.856±2527.0849 5564.254±2451.4327 
AUC0-inf (ng.hr/mL) 6491.992±2558.0749 5759.936±2493.6955 
Kel (1/hr) 0.125±0.0362 0.121±0.0328 
t½ (hr) 6.048±1.8252 6.161±1.7626 
(AUC0-t/AUC0-inf) *100 3.468±1.9416 3.652±1.7437 
*Median, Minimum and Maximum values reported for Tmax. 
 




100.0%.  The ratio of geometric least squares mean of 
test product (A) and reference product (B) treatments 
of log-transformed pharmacokinetic parameter AUC0-t 
was 118.11%. For AUC0-t the two one-sided 90% 
confidence interval for the ratio of the geometric least 
squares mean was found 112.58-123.92 % with power 
100.0 %. For the log-transformed pharmacokinetic 
parameter AUC0-inf the ratio of geometric least 
squares mean of test product (A) and reference product 
(B) treatments was 117.17 % and the two one-sided 
90% confidence interval for the ratio of geometric least 
squares mean was found 111.97-122.61 % with power 
100.0%. In DRV for all the pharmacokinetic 
parameters the 90% confidence interval is within the 
acceptance limits of 80.00 – 125.00% (Table 9). 
For RTV the ratio of geometric least squares mean 
of test product (A) and reference product (B) 
treatments of log-transformed pharmacokinetic 
parameter Cmax and AUC0-t was 112.37% and 
114.98% respectively. The two one-sided 90% 
confidence interval for the ratio of the geometric least 
squares mean for the Cmax and AUC0-t was found 
106.02-119.11 % and 109.84-120.36% with power 
100.0% respectively. In case of log-transformed 
pharmacokinetic parameter AUC0-inf the ratio of 
geometric least squares mean of test product (A) and 
reference product (B) treatments of was 114.76%. The 
two one-sided 90% confidence interval for the ratio of 
geometric least squares mean for AUC0-inf was 
found 109.92-119.81 % with power 100.0 %. For 
RTV also all the pharmacokinetic parameters are 
within the acceptance limits of 80.00-125.00% at 90% 
confidence interval. The Group*Formulation effect 
was found statistically insignificant for the 
pharmacokinetic parameters Cmax, AUC0-t and 
AUC0-∞ on log-transformed data for both DRV and 
RTV. The linear and semi log plot of mean plasma 
concentration versus time curves of Darunavir and 
Ritonavir after administration of test product (A) and 
reference product (B) under fed conditions are 
represented in Fig. 2 and Fig. 3 that indicates the test 
product (A) compared to the Reference product (B), 
met the bioequivalence criteria under fed conditions. 
 
Discussion 
The current study reports the development, 
validation, and clinical application of a novel 
bioanalytical method of DRV and RTV using 
electrospray ionization (ESI) in the positive ionization 
mode with DRV-D9, and RTV-D6 as the respective 
internal standards. This study exclusively reports the 
simultaneous quantification of DRV and RTV. The 
chromatographic conditions were optimized to have 
adequate response, good peak shapes and shorter run 
time, under isocratic conditions on an HPLC system 
connected with mass spectrometry using Thermo 
Hypersil Gold column (50×4.6mm, 3μ). All mass 
parameters were suitably optimized to obtain a stable 
and adequate response for the analytes. The difference 
Table 9 — Statistical results for DRV and RTV test and reference products under fed condition. 







Test product (A) Reference product (B) (A/B) % (A vs. B) 
DRV 
Cmax (ng/mL) 8929.135 7819.385 114.19 12.7 100 110.39-118.13 
AUC0-t (ng.hr/mL) 91693.847 77633.630 118.11 18.0 100 112.58-123.92 
AUC0-inf (ng.hr/mL) 97293.655 83035.569 117.17 17.0 100 111.97-122.61 
RTV 
Cmax(ng/mL) 876.584 780.061 112.37 21.9 100 106.02-119.11 
AUC0-t (ng.hr/mL) 5825.403 5066.554 114.98 17.1 100 109.84-120.36 




Fig. 2 — (A)Linear and (B) semi log plot of mean plasma 
concentration versus time curves of DRV after administration of 
test product (T) and reference product (R) under fed conditions. 




in retention time of DRV and RTV were 2.32 and 
3.91 mins respectively and for the Internal standard 
(DRV-D9 and RTV-D6) 2.30 and 3.86 mins 
respectively, allowing a good separation for both the 
analytes. Further, use of deuterated internal standards 
helped to compensate variability during extraction 
and HPLC-MS/MS analysis. 
The validation was carried out as per US FDA 
guidelines. The parameters determined were 
selectivity, sensitivity, matrix effect, linearity, 
precision, accuracy, recovery, stability and dilution 
integrity. No Matrix effect was observed for six 
different lots of K3-EDTA plasma and the blank 
plasma samples were also analyzed to confirm the 
absence of direct interferences. The results of the 
P&A batches confirm the reproducibility of the 
method with an excellent ruggedness for different 
analyst and column. This optimized and validated 
LC–MS/MSmethod was applied to quantify plasma 
DRV and RTV concentration for a bioequivalence 
study in 77 healthy subjects(dosed in 3 groups)after 
oral administration of test DRV/RTV tablets 
400/50mg (Dose; 02 x 400/50 mg) with reference 
PREZISTA
®
 (DRV) tablets 800 mg of Janssen Ortho 
LLC Gurabo, PR 00778 and NORVIR
®
 (RTV) 
Tablets 100 mg of AbbVie Inc, North Chicago, IL 
60064, U.S.A under fed conditions.   
 
Conclusion 
The current study describes a LC-MS/MS assay 
method for the rapid, simple and sensitive 
quantification of both DRV and RTV in human 
plasma. The developed method was validated by 
following the US FDA guidelines. The study is 
unique and reports the simultaneous assay and 
sensitive determination of both DRV and RTV in 
human plasma that was further applied for 
pharmacokinetic studies in humans. The developed 
method can be further used in routine therapeutic drug 
monitoring to quantify both DRV and RTV or in 




DRV: Darunavir; RTV: Ritonavir; FDA: Food and 
Drug Administration; Cmax: Maximum plasma 
concentration; ICH: International Conference on 
Harmonization; HPLC: High Performance Liquid 
Chromatography; USA: United State on America; 
LCMS: Liquid Chromatography; Mass Spectrometry; 
K3EDTA: Tripotassium Ethylene Diamine Tetra 
Acetate; BE: Bioequivalence; LLOQ: Lower Limit of 
Quantification; MS: Mass Spectrometry; GS: Gas; 
DP: Clustering Potential; EP: Entrance Potential; CE: 
Collision Energy; CXP: Cell Exit Potential; QC: 
Quality Control, CS: Calibration Standard; WIS: 
Working Internal Standard; HLB: Hydrophilic 
Lipophilic Balance; EMA: European Medicines 
Agency; LQC: Low QC; MQC: Med QC; HQC: High 
QC; DQC: Diluted QC; ULOQ: Upper Limit of 
Quantification; PB: Plasma Blank; GCP: Good 
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